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ABSTRACT:
Objective: We aimed to demonstrate non-inferiority of delayed cord clamping (DCC) and cord milking (CM) in comparison 
to early cord clamping (ECC) in the incidence of hyperbilirubinemia requiring phototherapy. 
Material and methods: 467 of maternal-foetal dyads were screened for eligibility. 389 term infants, of breastfeeding, 
non-smoking mothers were randomized to receive ECC (< 40 s), DCC (1–2 min) or CM (4 times towards the neonate). The 
primary outcome was defined as hyperbilirubinemia requiring phototherapy. 
Results: 307 patients were included in the analysis. CM did not increase the risk of phototherapy RR 11.27 95% CI (0.80; 
2.04). Similar results were achieved when comparing DCC and ECC, RR 1.29 95% CI (0.82; 2.05). This was also true for CM vs 
DCC, RR 0.99 95% CI (0.64; 1.52). The prevalence of total serum bilirubin (TSB) at 24–48 hours was 10.8 mg/dL; 10.33 mg/dL 
and 11.39 in ECC, CM and DCC group respectively. Transcutaneous bilirubin (TcB) levels at 24–48 h were 7.58 mg/dL, 
7.89 mg/dL and 7.60 mg/dL in the ECC, CM and DCC respectively. None of the neonates met exchange transfusion criteria 
or symptomatic polycythaemia. 
Conclusions: Our study suggests that placental transfusion is not associated with hyperbilirubinemia requiring photo-
therapy or exchange transfusion.
Key words: jaundice; hyperbilirubinemia; neonate; placental transfusion
Ginekologia Polska 2020; 91, 10: 1–7
INTRODUCTION
Delayed cord clamping (DCC), also known as expect-
ant or physiological cord clamping, has been a subject of 
extensive research for the last couple of years. It involves 
clamping the cord when pulsation has ceased or at least 
after 30–60 seconds, allowing for foetal blood transfer from 
the placenta to the infant [1]. Cord milking (CM), an alterna-
tive method, involves milking the cord towards the infants 
4 times. These interventions, labeled as placental transfusion, 
can provide the infant with respectively up to 30% and 60% 
additional blood volume and red blood cells [2]. Numerous 
neonatal benefits of DCC have been suggested including 
increased haemoglobin and ferritin levels both at birth and 
at longer term [3]. Nevertheless, systematic reviews of DCC 
versus early or immediate cord clamping (ECC) reveal that it 
may also contribute to other neonatal outcomes including 
polycythaemia and hyperbilirubinemia [2–4]. 
A Cochrane review published in 2008 determined mater-
nal and neonatal effects of different policies of cord clamp-
ing timing during the third stage of labour in term infants 
[3]. Eight trials examined jaundice requiring phototherapy. 
However, evidence for decreased risk of jaundice requiring 
phototherapy in the ECC group was based upon one unpub-
lished trial. The variable did not reach statistical significance 
if this one trial was removed from the analysis. No difference 
was detected for polycythaemia. A meta-analysis published 
by Hutton provides contradictory results [5]. No significant 
differences were found between groups. Recently, a large 
study from Australia was published where the authors found 
that in preterm infants DCC did not increase the risk of 
hyperbilirubinemia [6]. Nevertheless, a systematic review 
from the same group showed that there was a significant 
increase in polycythaemia and jaundice [7]. It is important to 
note, that none of the reviews distinguished between DCC 
and CM, as opposed interventions to ECC. Based on numer-
ous proven benefits, placental transfusion has been widely 
adopted in perinatal centres (personal communication) and 
is now part of both Polish and international guidelines on 
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neonatal resuscitation [1]. A retrospective study published 
by Yang et al. has shown that implementing placental trans-
fusion as a unit protocol did not increase the number of 
infants requiring phototherapy [8]. We are the first to report 
a prospective double blinded randomised controlled trial.
Objectives
The primary end point of this study was to evaluate if 
placental transfusion (delayed cord clamping or cord milk-
ing) increases the risk hyperbilirubinemia requiring photo-
therapy in term infants. 
MATERIAL AND METHODS
We conducted a trial using observer blinded, balanced 
randomization [1:1:1], and included 3 parallel groups. We 
planned to demonstrate the non-inferiority of placental 
transfusion in comparison to ECC in regard to the incidence 
of hyperbilirubinemia requiring phototherapy.
Eligible participants were maternal-foetal dyads, in la-
bour at 37–42 weeks of gestation. We recruited non-smok-
ing mothers, willing to return for follow up visits, who de-
clared to breastfeed for at least 6 months. Exclusion criteria 
included iso-immune haemolytic disease, sepsis, maternal 
Gilbert syndrome, birth asphyxia, need for resuscitation and 
serious maternal haemorrhage during delivery.
The study took place at a level III teaching hospital with 
approximately 3500 deliveries per year (2000 > 37 weeks of 
gestation) and 67 neonatal beds. During the trial, the local 
protocol on cord clamping had not been yet adjusted to 
the new International Liaison Committee on Resuscitation 
(ILCOR) guidelines [1]. 
A member of the recruitment team approached the 
mothers prior to delivery in the labour ward. He/she ex-
plained the study and obtained written consent for par-
ticipating in the trial. The patient’s medical record number 
(MRN) was registered on a secure web-based platform and 
demographic data was recorded. Maternal-foetal dyads, prior 
to delivery, were randomly assigned to receive ECC, DCC or 
CM. The midwife or obstetrician was informed about the al-
located intervention preceding the delivery of the shoulders 
(spontaneous vaginal delivery), or head (caesarean section). 
During vaginal deliveries midwifes were asked to main-
tain the infant at least 10 cm above the uterus until the cord 
is clamped, as this has been found to be most effective in 
obtaining adequate blood volumes [9, 10]. In cases of cae-
sarean sections, the baby was placed on the mother’s laps 
and swaddled in sterile towels to prevent heat loss. In the 
ECC and DCC group, the recruiter informed the team when 
30 seconds or 2 minutes had passed. The attending labour 
ward staff clamped the cord afterwards. 
If CM was applied the baby was placed about 20 cm 
below the level of the placenta, between the mother’s thighs 
(during a vaginal delivery) or at the side of the mother, 
swaddled in sterile towels (during a caesarean delivery). 
Before starting the trial we piloted this procedure previously 
described by Rabe et al. [11]. We assumed that the placental 
would contain about 40% of total circulating foetal blood 
with about 10–15 mL present for placental transfusion in the 
umbilical vein, both during a vaginal and caesarean delivery 
[12]. If the cord was milked once at the speed of 20 cm/2 sec-
onds, we were able to transfer approximately 10–13 mL of 
blood to the neonate. Under the assumption that the cord 
vein will rapidly refill itself, we assumed that milking the cord 
four times would give us 30–40 mL of blood. This amount is 
similar to the quantity of blood transfused to the neonate 
during DCC [11]. A member of the delivery team (vaginal 
delivery) or operating team (caesarean section) held the 
cord at the level of the introitus or caesarean wound and 
milked the cord four times towards the neonate counting 
out loud. The cord was clamped after the fourth milking.
The primary endpoint with respect to the risk of hy-
perbilirubinemia, was the number of neonates requiring 
phototherapy or exchange transfusion as defined by the 
American Academy of Paediatrics (AAP) guidelines [13]. 
Infants were assessed for the risk of developing hyperbili-
rubinemia or the need for exchange transfusion based on 
gestational age and risk factors as defined by Bhutani et al. 
[13]. If levels exceeded predefined thresholds, phototherapy 
was applied. In infants receiving treatment, bilirubin levels 
were reordered every 48 hours as per unit protocol.
The secondary objectives were to determine if DCC or 
CM compared to ECC, influenced the risk for polycythaemia 
during the first week of life, congenital anaemia, and read-
mission for hyperbilirubinemia during the first two weeks 
of life. Polycythaemia was defined as venous haematocrit 
of more than 65% or venous haemoglobin above 22 g/dL. 
Congenital anaemia was diagnosed in babies with cord 
haemoglobin < 12.5 g/dL [14]. The decision for readmission 
for hyperbilirubinemia was based on the AAP guidelines for 
initiating phototherapy [15]. 
Sample sizes were estimated based on proportions of 
neonates in need of phototherapy between groups reported 
by McDonald (8.8% and 4.1% of neonates with jaundice in the 
DCC and ECC group respectively) [16]. Initially we calculated 
that, to detect a higher prevalence of neonates requiring 
phototherapy in the DCC group with one-tailed α value of 
0.05 and 80% power, 380 children should be enrolled in every 
group (1140 children in total). Unfortunately, we were only 
able to secure limited funds to complete the study, which 
forced us to significantly decrease the number of participants. 
The patient’s MRN was registered by one of the recruiters 
on a secure web-based platform, initial demographic data 
was recorded, and a random computer-generated treatment 
was allocated. Randomization was created by Blockrand 
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software (R Foundation for Statistical Computing, Vienna, 
Austria). Block randomization by delivery mode was ap-
plied. Patients were randomly assigned to ECC, DCC or CM 
in a 1:1:1 ratio. The block size was variable and concealed 
until primary endpoint analyses.
Due to the nature of the intervention, we could not take 
any measures to blind the intervention, however caregivers 
deciding on the initiation of phototherapy were blinded to 
intervention allocation. To prevent bias, members of the 
recruitment team did not participate in the further care of 
neonates on postnatal wards. 
Venous cord blood samples were collected for each 
maternal-neonate dyad. Non-invasive transcutaneous bili-
rubin levels (TcB) were evaluated using a bilirubinometer 
(Bilicheck, Philips, Andover, MA, USA) every 24 hours during 
evening nursing rounds until discharge. The bilirubinometer 
was calibrated prior to every measurement, as per manu-
facture’s recommendation. Venous samples for total serum 
bilirubin (TsB) were ordered on the discretion of the attend-
ing physician or if TcB extended recommended levels [17]. 
Olympus AU 480 (Beckman Coulter, Fullerton, CA, USA) was 
used to measure TsB. The analyser’s calibration was checked 
with appropriate controls as per product guidelines. 
Statistical comparison of baseline demographics be-
tween groups was performed using chi-squared test for 
frequency data. For continuous variables t-test was used 
when Shapiro-Wilk test did not rejected assumption of nor-
mality, otherwise Wilcoxon rank sum test was used. For the 
assessment of primary and secondary endpoints, 95% CI 
and p values for frequency data were calculated assuming 
normal approximation of a binomial distribution. To assess 
phototherapy duration and hospitalization duration, a com-
parison Wilcoxon rank sum test was used.
The local Bioethics Committee approved the study. Our 
study is registered with ClinicalTrials.gov. 
RESULTS
Recruitment was conducted from January 2014 to June 
2016. We approached 467 eligible women in labour and 
invited them to take part in the trial. Seventy-eight women 
either declined participation or were not enrolled for opera-
tive reasons. The remaining 389 maternal-foetal dyads were 
randomly assigned to 3 interventions (Fig. 1). 
Compliance with allocated treatment was 96.9%, 91.5% 
and 90.1% in the ECC, CM and DCC groups respectively. 
Reasons for allocation deviation are presented in Fig1. Study 
groups were similar with respect to demographic and clini-
cal variables (Tab. 1).
Primary outcomes
The primary analysis was planned as modified inten-
tion-to-treat (mITT) and included all patients, who were 
randomly assigned to procedures and passed inclusion and 
exclusion criteria. The initially planned number of patients 
was not achieved due to funding limitations. Forty-one in-
fants were excluded from the analysis, including 26 neonates 
lost for follow-up or with incomplete data before assessment 
of eligibility criteria or reaching the primary endpoint (Fig. 1). 
In these cases, the reason for attrition was not known, which 
can lead to the bias. 
The number of children who were randomized and 
passed inclusion/exclusion criteria was 109, 99 and 109 in 
ECC, CM and DCC group, respectively (Fig. 1). 
To perform mITT analysis of the primary outcome, a sin-
gle imputation method was planned to substitute missing 
data. Given the size of groups, the imputation could have 
substantial impact on the proportion of phototherapy which 
can lead to bias on estimated parameters but has little effect 
on the low power of the non-inferiority test, therefore per 
protocol primary outcome analysis was performed.
The percentage of neonates requiring phototherapy did 
not differ significantly between the ECC, CM and DCC group 
(23%, 29% and 29%, respectively). CM compared to ECC did 
not increase the risk of phototherapy, with a mean difference 
between two treatment arms of 6.2% and RR 1.27 95% CI 
(0.80; 2.04). Similar results were achieved when comparing 
DCC and ECC, with a mean difference of 6.6% and RR 1.29 95% 
CI (0.82; 2.05). This was also true for both methods of placental 
transfusion (CM vs DCC) RR 0.99 95% CI (0.64; 1.52) (Tab. 2).
For the non-inferiority analysis, the non-inferiority mar-
gin was set at 4% as the largest difference being clinically ac-
ceptable. We did not find published data regarding neonatal 
jaundice requiring phototherapy in neonates receiving cord 
milking, thus we assumed the same non-inferiority margin 
for all comparisons. 
The non-inferiority of both therapies was assessed based 
on whether the pre-specified treatment effect falls within 
95% one-tailed interval for the treatment effect, which is the 
same as the upper limit of a two-tailed 90% CI. The non-in-
feriority margin was within 90% of the two-tailed CI for the 
absolute risk difference between CM and ECC (–3.9; 16.3%) 
and for the absolute risk difference between DCC and ECC 
(–3.3%; 16.5%). Given that obtaining adequate sample size 
in our study was infeasible and the small statistical power of 
non-inferiority test (12% for CM vs ECC, and 13% for DCC vs 
ECC), a conclusive decision cannot be made about non-in-
feriority of CM and DCC procedures with respect to ECC. 
Secondary outcomes
The prevalence of total serum bilirubin (TSB) at 24–
48 hours was in all study groups. The average time (hours) 
of phototherapy was 58.0 in the ECC group, 49.1 in the 
CM group and 63.4 in the DCC group (Tab. 2). None of the 
patients had asymptomatic or symptomatic polycythaemia 
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(defined as a haematocrit > 65%). One infant in the ECC 
group (n = 26), none in the CM group (n = 24) and 5 neonates 
in the DCC group (n = 39) presented with venous haemo-
globin above 22 g/dL (Tab. 2). One patient per group (CM 
and DCC) required a second course of phototherapy prior 
to discharge. On average, infants from ECC group were dis-
charged home at 4.1 days, while infants from CM and DCC 
groups were hospitalized for 4.4 and 4.5 days, respectively. 
DISCUSSION
A meta-analyses estimated a significant 47% reduction 
in the risk of anaemia and 33% reduction in the risk of iron 
Analysed (n = 106)
ECC (n = 124)
Excluded from analyses post delivery 
(n = 18)
• Gestation age < 37 weeks (n = 2)
• HDN (n = 1)
• Asphyxia (n = 2)
• Congenital abonormalities (n = 1)
• Sepsis (n = 1)
• Albumin < 3g/L (n = 1)
• Incomplete data (n = 7)
• Lost to follow up (n = 3) 
CM (n = 117)
Excluded from analyses post delivery 
(n = 20)
• HDN (n = 2)
• Early jaundice (n = 1)
• Respiratory Distress (n = 3)
• Albumin < 3g/L (n = 5)
• Incomplete data (n = 7)
• Lost to follow up (n = 2)
Analysed (n = 97)
Randomised (n = 400)
Excluded due to inclusion/exclusion criteria (n = 65):
• Declined to participate (n = 44)
• Delivery not at 37–42 weeks gestation (n = 1)
• Smoker (n = 1)
• Not willing to return for follow up visits (n = 12)
• Participation in another trial (n = 3)
• Maternal Gilbert syndrome (n = 5)
• Hematocrit < 10g/L (n = 8)
Not specied (n = 2) 
Enrollm
ent
DCC (n = 118)
Excluded from analyses post delivery 
(n = 12)
• HDN (n = 1)
• Asphyxia (n = 3)*
• Congenital abnormalities (n = 1)*
• Respiratory distress (n = 2)
• Albumin < 3g/L (n = 1)
• Incomplete data (n = 2)
• Lost to follow up (n = 3)
Follow
-up
Analysed (n = 106)
A
nalyses
Assessed for eligibility (n = 467)
Allocated to ECC (n = 133)
Received allocated intervention (n = 125)
• Maternal haemorrhage (n = 3)
• Newborn respiratory distress (n = 1)
• Lost to follow-up (n = 4)
A
llocation
Allocated to DCC (n = 133)
Received allocated intervention (n = 118)
• Maternal haemorrhage (n = 7)
• Newborn respiratory distress (n = 4)
• Need for resuscitation (n = 1)
• Discharge against medical advice (n = 1)
• Lost to follow-up (n = 2) 
Allocated to CM (n = 134)
Received allocated intervention (n = 118)
• Maternal haemorrhage (n = 6)
• Newborn respiratory distress (n = 4)
• Need for resuscitation (n = 1)
• Lost to follow-up (n = 5)  
Lost to follow up (n = 1)Lost to follow up (n = 1)
Figure 1. Randomization flow chart
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deficiencies at ages 2 to 3 months in the DCC group [18–20]. 
Nonetheless, it is also important to understand, whether 
placental transfusion may also contribute for less favourable 
neonatal outcomes such as hyperbilirubinemia, (requiring 
phototherapy or exchange transfusion) and polycythaemia.
To our best knowledge, this is the first study, which was 
designed, to demonstrate that applying DCC or CM to term 
infants does not increase the risk of hyperbilirubinemia 
requiring phototherapy or exchange transfusion without 
harmful effects in comparison to ECC. The frequency of 
infants requiring phototherapy in CM or DCC groups was 
higher than in ECC group. However, due to small sample 
size, the non-inferiority analysis of the primary outcome was 
inconclusive. Perhaps, early cord clamping at only 30 sec-
onds (similarly to previous authors), would have provided 
a larger difference in outcome data [21]. 
Postnatal hyperbilirubinemia is universal and manifests 
as neonate jaundice in over 60–80% of all neonates [13]. If 
left untreated, hyperbilirubinemia may progress to exces-
sive levels that may be associated with evident bilirubin 
Figure 2. Transcutaneous bilirubin levels during the first 24–96 hours of life














Male 49.1% 43.3% 48.1% 0.411 0.891 0.492
Female 50.9% 56.7% 51.9%
Mean (SD) birth weight, g 3503 (459) 3485 (399) 3551 (546) 0.767 0.493 0.328
Mean (SD) gestational age, wk 39.11 (0.99) 39.00 (1.01) 39.01 (1.07) 0.538 0.448 0.884
Method of childbirth, %
Spontaneous vaginal delivery 53.8% 43.3% 48.1% 0.136 0.410 0.492
Caesarean section 46.2% 56.7% 51.9%
Median APGAR1 (Q1, Q3) 10 (10, 10) 10 (10, 10) 10 (10, 10)
Proportion APGAR1 < 10% 8.5% 8.2% 5.7% 0.950 0.422 0.468
Median APGAR5 (Q1, Q3) 10 (10, 10) 10 (10, 10) 10 (10, 10)
Proportion APGAR5 < 10% 6.6% 5.2% 6.6% 0.662 1.000 0.662
Mean (SD) cord blood Hb, g/dL 16.80 (1.93) 16.33 (2.22) 16.62 (2.22) 0.072 0.263 0.406
Mean (SD) cord blood bilirubin, mg/dL 2.07 (0.63) 2.06 (0.55) 1.93 (0.49) 0.809 0.097 0.162
Maximum value 4.4 3.54 3.82
Mean (SD) transcutaneous bilirubin (first 24 hours), mg/dL 4.20 (2.06) 4.19 (1.71) 3.99 (1.87) 0.995 0.581 0.499
Range (min; max) [0; 10] [1.2; 9.1] [0; 8.7]
Mean (SD) cord albumin, g/dL 3.50 (0.25) 3.48 (0.24) 3.44 (0.23) 0.644 0.083 0.197
ECC — early cord clamping; CM — cord milking; DCC — delayed cord clamping; IQR — interquadral; SD — standard deviation; Hb — hemoglobin
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neurotoxicity. Available results from other studies regarding 
“jaundice” and “jaundice needing phototherapy” (associated 
with DCC) can be misleading. First, no information is offered 
on how “clinical jaundice” was assessed on examination, and 
estimation of the degree of hyperbilirubinemia based solely 
on clinical examination can lead to errors [22–24]. A review 
on DCC revealed only 4 studies which assessed polycythae-
mia and hyperbilirubinemia during the first week of life as 
a second objective [25]. No information was provided on 
which hour of life the bilirubin levels were measured exactly. 
In our study, to avoid loss or delay in diagnosis we screened 
all participants for jaundice using a bilirubinometer. Further-
more, guidelines to treat jaundice have changed over time 
and none of the studies mentioned what threshold was used 
for administering phototherapy. No information is given 
whether staff responsible for phototherapy administration 
was blinded to the type of cord clamping intervention. 
In view of the decrease sample size, our results may 
underestimate the true prevalence of hyperbilirubinemia 
requiring phototherapy. Additional subgroup analyses to 
identify the risk of readmission secondary for jaundice, anae-
mia and iron storages at 3 months of age will be a subject 
of a separate publication. Possible confounders such as 
maternal pre-gestational diabetes, iso-immune haemolytic 
disease, were not included in the analysis, which may alter 
the results. 
CONCLUSIONS
With early detection of hyperbilirubinemia and prompt 
initiation of treatment following accepted guidelines, a pos-
sible elevated risk of bilirubin encephalopathy can be mini-
mized, while preserving all potential benefits of the placen-
tal transfusion in term infants.
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